IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · IEX Real-Time Price · USD
1.190
-0.010 (-0.83%)
At close: Apr 30, 2024, 4:00 PM
1.209
+0.019 (1.60%)
After-hours: Apr 30, 2024, 6:54 PM EDT
IceCure Medical Revenue
In the year 2023, IceCure Medical had annual revenue of $3.23M with 4.67% growth. Revenue in the quarter ending December 31, 2023 was $1.26M with 33.65% year-over-year growth.
Revenue (ttm)
$3.23M
Revenue Growth
+4.67%
P/S Ratio
16.71
Revenue / Employee
$45,479
Employees
71
Market Cap
54.42M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3.23M | 144.00K | 4.67% |
| Dec 31, 2022 | 3.09M | -1.05M | -25.45% |
| Dec 31, 2021 | 4.14M | 270.00K | 6.98% |
| Dec 31, 2020 | 3.87M | 2.24M | 137.74% |
| Dec 31, 2019 | 1.63M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionICCM News
- 15 days ago - IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer - PRNewsWire
- 27 days ago - IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance - PRNewsWire
- 4 weeks ago - IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes - PRNewsWire
- 4 weeks ago - IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024 - PRNewsWire
- 6 weeks ago - IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy - PRNewsWire
- 7 weeks ago - IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes - PRNewsWire
- 7 weeks ago - IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference - PRNewsWire
- 2 months ago - IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024 - PRNewsWire